9 active not recruiting. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 9 |
| Phase 1 | 3 | Active not recruiting 3 |
Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI L-Carnitine, The standard care for the management of myocardial infarction post PCI - Reperfusion Injury, Myocardial, Myocardial Infarction | Phase 2 | Active not recruiting | Ain Shams University | 76 | 2025-06-01 | 2026-09-01 |
| Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once - STEMI, STEMI (ST Elevation MI) | Phase 1 / Phase 2 | Active not recruiting | Implicit Bioscience | 10 | 2025-02-06 | 2026-03-27 |
| High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI Statin monotherapy (rosuvastatin or atorvastatin), Placebo - ST Elevation (STEMI) Myocardial Infarction | Phase 2 | Active not recruiting | Sheikh Zayed Federal Postgraduate Medical Institute | 66 | 2024-12-02 | 2025-04-11 |
| Empagliflozin for No-reflow Phenomenon in PCI for STEMI Empagliflozin 25 milgrams (Mg), Empagliflozin 10 Mg - STEMI, No-Reflow Phenomenon | Phase 2 | Active not recruiting | Instituto Nacional de Cardiologia Ignacio Chavez | 162 | 2024-08-22 | 2026-04-15 |
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Istaroxime, Placebo - Cardiogenic Shock | Phase 1 / Phase 2 | Active not recruiting | Windtree Therapeutics | 20 | 2024-06-01 | 2025-08-20 |
| CERebrolysin In CADASIL Cerebrolysin, 0.9 % NaCl - Cadasil | Phase 2 | Active not recruiting | Ever Neuro Pharma GmbH | 30 | 2023-11-29 | 2025-02-25 |
| Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock Tocilizumab, Dobutamine, NaCl 0.9% - Acute Myocardial Infarction, Cardiogenic Shock | Phase 2 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 100 | 2022-03-13 | 2025-07-17 |
| BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) BGC101 (autologous EnEPC preparation), Control medium - Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | Phase 1 / Phase 2 | Active not recruiting | BioGenCell Ltd. | 40 | 2016-06-01 | 2025-06-06 |
| The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial Plasma-Lyte A and 25% Autologous Plasma, Autologous EPCs, Autologous EPCs Transfected with human eNOS - Anterior Wall Myocardial Infarction | Phase 2 | Active not recruiting | Ottawa Hospital Research Institute | 47 | 2013-07-19 | 2025-08-15 |
ST Elevation Myocardial Infarction (4) · Myocardial Infarction (3) · Shock, Cardiogenic (2) · Anterior Wall Myocardial Infarction (1) · CADASIL (1) · Chronic Limb-Threatening Ischemia (1) · Inflammation (1) · Myocardial Reperfusion Injury (1) · No-Reflow Phenomenon (1) · Peripheral Arterial Disease (1) · Peripheral Vascular Diseases (1)
Cardiovascular Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Vascular Diseases (9) · Infarction (8) · Necrosis (8) · Heart Diseases (7) · Myocardial Ischemia (7) · Myocardial Infarction (4) · Shock (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Atherosclerosis (1) · Brain Diseases (1)
Sodium Chloride (2) · Atorvastatin (1) · Carnitine (1) · Dobutamine (1) · Istaroxime (1) · Lactic Acid (1) · Plasmalyte A (1) · Rosuvastatin Calcium (1) · atibuclimab (1) · cerebrolysin (1) · empagliflozin (1) · tocilizumab (1)
Ain Shams University (1) · BioGenCell Ltd. (1) · Copenhagen University Hospital, Rigshospitalet (1) · Ever Neuro Pharma GmbH (1) · Implicit Bioscience (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Ottawa Hospital Research Institute (1) · Sheikh Zayed Federal Postgraduate Medical Institute (1) · Windtree Therapeutics (1)
United States (3) · Israel (2) · Argentina (1) · Canada (1) · Czechia (1) · Denmark (1) · Egypt (1) · Italy (1) · Mexico (1) · Pakistan (1) · Poland (1)
Alexander Reyzelman, MD (1) · Alisha Oropallo, MD (1) · Antonio Abbate, MD, PhD (1) · Caitlin Hicks, MD (1) · Duncan Stewart, MD, FRCP C (1) · Edouard Aboian, MD (1) · Eduardo Arias-Sanchez, MD (1) · Igor Laskowski, MD (1) · Jeffrey J Siracuse, MD (1) · Khanjan Nagarsheth, MD (1) · Marc Sintek, MD (1) · Mark Wyers, MD (1) · Martin Frydland, MD, PhD (1)
PMID 30992077, PMID 31127491, PMID 31759100, PMID 31779619, PMID 32396609, PMID 32539724, PMID 32717242, PMID 34712142, PMID 34896968, PMID 35705980, PMID 41230400